

Atypical pneumonia (Review)

VASILIKI EPAMEINONDAS GEORGAKOPOULOU¹, IOANNIS G. LEMPESIS¹, KYRIAKOS TARANTINOS²,
PAGONA SKLAPANI³, NIKOLAOS TRAKAS³ and DEMETRIOS A. SPANDIDOS⁴

¹Department of Pathophysiology, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, 11527 Athens, Greece; ²First Department of Respiratory Medicine, Sismanogleio Hospital, 15126 Athens, Greece; ³Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece; ⁴Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece

Received January 5, 2024; Accepted August 30, 2024

DOI: 10.3892/etm.2024.12713

Abstract. Atypical pneumonia encompasses diverse pathogens, such as *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella* species, which differ from typical bacterial pneumonia in their extrapulmonary manifestations. Clinical differentiation relies on systemic involvement rather than on standalone symptoms. Despite challenges in distinct diagnosis, syndromic approaches and weighted point systems aid in accurate presumptive diagnoses. Antibiotic treatment, often non- β -lactams due to the unique cell structures of atypical pathogens, targets intracellular processes. Macrolides, tetracyclines, quinolones and ketolides are effective due to their intracellular penetration, crucial for combating these intracellular pathogens. The prevalence of atypical pneumonia varies globally, with Europe, Asia/Africa and Latin America reporting detection rates between 20-28%. *Streptococcus pneumoniae* remains a primary cause of pneumonia; however, atypical pathogens contribute significantly to this disease, being more prevalent in outpatient settings and among young adults. *Legionella* stands out in severe hospitalized cases and is associated with higher mortality rates. Diagnosis proves challenging due to overlapping symptoms with other respiratory infections. Differentiation among pathogens, such as *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella* relies on subtle clinical variations and imaging findings. Diagnostic methods include serological studies, cultures and polymerase chain reaction, each with limitations in sensitivity or specificity. Prognosis varies widely. Atypical pneumonia can progress to severe forms with fatal outcomes, causing multi-organ damage. Complications extend beyond the respiratory system, affecting

the cardiovascular system, exacerbating conditions such as chronic obstructive pulmonary disease and asthma, and potentially linking to conditions such as lung cancer. Increasing antibiotic resistance poses a significant challenge, influencing treatment outcomes and prolonging illness duration.

Contents

1. Introduction
2. Prevalence of atypical pneumonia
3. Diagnostic approach
4. Treatment
5. Prognosis
6. Conclusions and future perspectives

1. Introduction

The term ‘atypical pneumonia’ was originally used to describe community-acquired pneumonias (CAPs) due to viruses that differed from bacterial CAPs as regards the clinical and radiologic features. Over time, this term has evolved to denote lower respiratory infections caused by specific respiratory microorganisms, including *Legionella* species, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Chlamydia psittaci* (psittacosis), *Coxiella burnetii* (Q fever) or *Francisella tularensis* (tularemia) (1-3).

CAPs differ from typical bacterial CAPs via several key mechanisms. Typical CAPs are most commonly caused by pathogens, such as *Streptococcus pneumoniae* and *Haemophilus influenzae*, which primarily present with more acute symptoms, such as a high fever, productive cough and localized chest pain. These infections are typically associated with radiographical findings of lobar consolidation and respond well to β -lactam antibiotics, which target the bacterial cell wall. By contrast, atypical CAPs are caused by pathogens such as *Legionella* species, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*, which often present with a more insidious onset, milder respiratory symptoms, and prominent extrapulmonary manifestations, such as headache, myalgia and gastrointestinal symptoms. Atypical pathogens generally lack cell walls or reside intracellularly,

Correspondence to: Dr Vasiliki Epameinondas Georgakopoulou, Department of Pathophysiology, Laiko General Hospital, Medical School of National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece
E-mail: vaso_georgakopoulou@hotmail.com

Key words: atypical pneumonia, *Legionella*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, respiratory infection

rendering them resistant to β -lactam antibiotics. As a result, treatment typically requires antibiotics that can penetrate cells, such as macrolides, tetracyclines or fluoroquinolones. Moreover, while typical CAPs usually exhibit well-defined lobar consolidation upon imaging, atypical CAPs often exhibit diffuse interstitial patterns or patchy infiltrates, reflecting their distinct pathophysiology and clinical course (1-3).

Atypical CAPs account for ~15% of all CAP cases. Although community outbreaks linked to atypical pneumonia pathogens exist, the majority of cases of atypical CAP are sporadic. These atypical microorganisms can occasionally result in outbreaks of pneumonia acquired in nursing homes or are acquired in medical facilities. Identifying atypical pneumonia as the cause of nosocomial infections is infrequent.

Among adults with less severe or ambulatory CAP, atypical microorganisms are more widespread compared to typical bacterial pathogens. *Legionella* notably contributes to severe CAP cases in hospitalized patients (4,5).

Atypical pneumonias can be clinically categorized into zoonotic transmission-based and non-zoonotic forms. Zoonotic atypical pneumonias encompass Q fever, psittacosis and tularemia, while non-zoonotic types involve CAPs caused by *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella*. Both zoonotic and non-zoonotic atypical pneumonias fundamentally differ from bacterial CAPs. Yet, the key distinguishing factor between atypical and typical CAP pathogens lies in the presence or absence of extrapulmonary indications. All atypical pulmonary pathogens, irrespective of their zoonotic or non-zoonotic nature, induce systemic infectious diseases primarily affecting the lungs (pneumonia). By contrast, pneumonias caused by *Moraxella catarrhalis*, *Streptococcus pneumoniae* or *Haemophilus influenzae* typically manifest with clinical findings and results from laboratory testing confined to the respiratory system. Once this differentiation is established in CAP cases with extrapulmonary signs, clinicians can identify the characteristic organ involvement pattern, facilitating focused diagnostic considerations (6,7).

Every atypical pulmonary pathogen displays a preference for particular extrapulmonary organ systems. What sets apart atypical pneumonias is individual clinical or laboratory findings, but also the distinct pattern of organ engagement. For instance, extrapulmonary organ involvement caused by *Legionella* markedly differs from that caused by *Chlamydia pneumoniae* or *Mycoplasma pneumoniae*, forming the basis for an initial clinical assessment. Identifying these unique extrapulmonary patterns linked to each atypical pathogen generally enables an accurate preliminary clinical diagnosis. However, this preliminary diagnosis is not definitive and should prompt targeted diagnostic tests to confirm or exclude specific pathogens (8).

The majority of research has not effectively distinguished typical from atypical pneumonias due to its focus on comparing the individual clinical and laboratory aspects of both pathogen types (9-12). These studies have found minimal discernible differences in standalone findings (9-12). Few studies have utilized a syndromic diagnosis (9-12), while only one study (10) employed a weighted syndromic point system. This system distinguishes atypical pneumonias by using a scoring system based on the presence of specific clinical features, such as symptoms and laboratory results, which are weighted according to their association with atypical pathogens. The weighted system

helps clinicians to prioritize testing and treatment for atypical pathogens when the clinical presentation aligns more closely with the characteristics typical of atypical pneumonias, such as the longer duration of symptoms before seeking care, the presence of certain epidemiological factors, and the absence of findings more common in typical bacterial pneumonias. Using this weighted approach, considering the relative clinical specificity of characteristic clinical findings, clinicians can effectively differentiate between typical and atypical pneumonias, even presumptively diagnosing Legionnaire's disease accurately (9-12). The significance of atypical pneumonias lies not merely in their clinical occurrence, but also in other clinical and public health considerations, demanding distinct therapeutic approaches compared to typical CAPs (13).

Atypical pathogens such as *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* are prevalent among young adults with CAP in outpatient settings, surpassing typical CAP-causing pathogens in this context. They, along with *Legionella*, significantly contribute to severe CAP cases. Unlike typical bacteria susceptible to β -lactam antimicrobial treatment due to their vulnerable cell walls, the majority of atypical pathogens lack these walls. Some are intracellular, such as *Legionella*, while others, such as *Mycoplasma pneumoniae*, use paracellular pathways for entry (14). Antimicrobials that disrupt intracellular protein synthesis effectively combat these atypical pathogens. Macrolides and tetracyclines impede bacterial protein synthesis inside cells. Quinolones and recently developed ketolides exhibit high efficacy against atypical pathogens, particularly *Legionella*. Given the intracellular nature of some atypical pathogens such as *Legionella*, effective antibiotic penetration into alveolar macrophages (AMs) is crucial. Macrolides, tetracyclines, quinolones and ketolides exhibit a tendency to accumulate in AMs (15-18).

Atypical CAP pathogens are more commonly encountered in outpatient cases and play a particularly crucial role in the severity of CAP among hospitalized patients. Additionally, public health concerns contribute to the significance of certain atypical CAP pathogens. *Chlamydia pneumoniae* infection is potentially involved in coronary artery disease and neurological diseases, such as multiple sclerosis. Moreover, infections from *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* could complicate asthma. Both pathogens are notable causes of nonexudative pharyngitis (19-25). Zoonotic atypical pneumonias have historically been pivotal in areas endemic to these diseases. Psittacosis continues to be a key factor in causing CAP among individuals who have contact with psittacine birds. Q fever sporadically occurs among those in proximity to parturient cats or in sheep-raising regions. Endocarditis poses an infrequent yet critical issue in endemic Q fever zones. Tularemia, with its various clinical presentations, may coincide with pneumonia. In endemic regions, tularemia remains a pertinent and potentially serious infectious disease (26-29). Atypical pathogens bear greater importance due to diagnostic challenges, susceptibility to non- β -lactam antibiotics, and the severity of associated complications.

2. Prevalence of atypical pneumonia

According to a previous study, the detectable rates of atypical pathogens differ across regions, with the rates being as follows:

North America at 22%, Europe at 28%, Latin America at 21% and Asia/Africa at 20% (30). Various countries and regions exhibit distinct rates of atypical pathogen detection.

The methods used to detect atypical pathogens, such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and *Legionella* species, can vary widely between regions. Some regions may rely more heavily on serological testing, which detects antibodies produced in response to infection, while others may use more advanced molecular techniques, such as polymerase chain reaction (PCR) or multiplex PCR, which directly identify the genetic material of the pathogens. PCR is generally more sensitive and specific but is also more costly and requires sophisticated laboratory equipment that may not be available in all regions.

In addition, the criteria used to diagnose atypical pneumonia can differ between regions due to variations in clinical guidelines, healthcare practices and the experience of healthcare providers. Some regions may adopt broader or more inclusive criteria that capture a wider range of cases, while others may use more stringent criteria, potentially leading to differences in detection rates. For example, the inclusion of certain clinical symptoms, the timing of sample collection, and the use of confirmatory tests such as paired serology can influence the reported prevalence of atypical pathogens (31).

The prevalence of atypical pathogens can be influenced by local epidemiological factors, including climate, population density and the prevalence of comorbid conditions. For instance, *Legionella* infections are more common in areas with certain environmental conditions, such as the presence of contaminated water sources. Additionally, variations in public health measures, vaccination rates and the presence of endemic diseases can affect the distribution and detection of atypical pathogens. Furthermore, regions with more advanced healthcare systems and better access to diagnostic tools are likely to have higher detection rates of atypical pathogens as they can employ more sensitive and specific diagnostic tests. By contrast, regions with limited healthcare infrastructure may have lower detection rates due to reliance on less sensitive methods or the unavailability of certain diagnostic technologies. Furthermore, differences in the methods through which health data are collected, reported and interpreted can also contribute to regional variations in detection rates. Some regions may have more robust surveillance systems and mandatory reporting of atypical pneumonia cases, leading to higher reported detection rates, while others might underreport cases due to lack of surveillance infrastructure or different public health priorities (31).

Europe. Previously, a survey on CAP outbreaks encompassing 3,523 patients (15% outpatients, 85% inpatients) between November, 1996 and July, 2008 revealed 1,463 patients with identifiable causes. *Streptococcus pneumoniae* emerged as the primary cause in Europe, accounting for 42% of the detectable rate, while atypical pathogens and mixed infections also played significant roles at 18 and 14%, respectively (32). In Spain, Capelastegui *et al* (33) noted a 50% detectable rate in their prospective study, where atypical pathogens were more prevalent among outpatients (67%) than inpatients (30.6%). In addition, two studies in The Netherlands highlighted *Streptococcus pneumoniae* as the primary cause of CAP,

with varying detectable rates for atypical pathogens (9 and 20%) (34,35).

Israel. Conversely, a study in northern Israel showcased a 52.4% detectable rate for atypical pathogens (*Chlamydia pneumoniae*, 20.6%, *Mycoplasma pneumoniae*, 18.3%, *Legionella pneumophila* 7.1%, and others) (36).

China. An extensive epidemiological survey conducted in China revealed results that differed from those in European countries (37). In that study, atypical pathogens were the primary cause of CAP. *Mycoplasma pneumoniae* was the most common pathogen, with a prevalence of 20.7%, followed by *Streptococcus pneumoniae* at 10.3% (37). Co-infections, particularly with bacteria and atypical pathogens, were prominent in community respiratory infections (37). In two national CAP surveys in performed China (38), *Mycoplasma pneumoniae* surpassed *Streptococcus pneumoniae* as the most common cause among adults, with rates of 38.9 and 32.6%, respectively. Chen *et al* (39) reported *Mycoplasma pneumoniae* as the predominant pathogen, with a positive percentage of 40.78%, exhibiting a significant association with seasons, particularly prevalent in late summer and autumn.

Chile. In Chile, among 356 patients, *Streptococcus pneumoniae* and viruses were predominant, with atypical pathogens contributing to 22% of the infections (40). In a clinical study conducted in Santiago, Chile, focusing on 104 patients with severe CAP between 2005 and 2006, the top seven identified etiological agents were observed. *Streptococcus pneumoniae* accounted for 26%, while *Legionella pneumophila* followed closely at 8.6%. Other pathogens included *Mycoplasma pneumoniae* (6%), *Chlamydia pneumoniae* (4%), Gram-negative bacillus (3%), influenza A virus (3%) and *Staphylococcus aureus* (3%). Notably, *Legionella pneumophila* ranks as the second etiological agent in severe CAP cases, following *Streptococcus pneumoniae*. The global mortality at 28 days in severe CAP was 25%, with *Legionella pneumophila* exhibiting a mortality rate of 33.3% (three out of nine cases); however, this difference was not significant when compared to non-*Legionella* severe CAP mortality (33 vs. 24.5%) (41).

USA and other regions. The incidence of *Legionella pneumophila* in CAP is relatively high worldwide, particularly in the USA (14%) (42) and Spain (12.5%) (43). Even in Asia, the incidence stands relatively high at 6.6% (43).

According to a previous study, the general occurrence of atypical pathogens such as *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella* among individuals experiencing severe pneumonia stood at 8.1%, varying widely from 0 to 48.1%. Notably, the prevalence in adults was slightly lower than that described in children. Notably, the combined group that did not differentiate between adults and children exhibited a prevalence of 12.1%, significantly influencing the overall prevalence rates (44).

3. Diagnostic approach

Clinical presentation. A schematic illustration of the key symptoms and clinical presentations of pathogens is presented




Figure 1. Schematic illustration providing a summary of the common symptoms and important clinical presentations of pathogens.

in Fig. 1. Pneumonia caused by *Chlamydia pneumoniae* manifests as a mild illness, primarily characterized by fever and cough, often followed by upper respiratory signs, such as rhinitis and a sore throat. In the study in 2013 by Conklin *et al* (45), the duration of cough ranged from 1 to 64 days, averaging ~21 days. While a non-productive cough is typically associated with this condition, ~70% of patients exhibited sputum production during *Chlamydia pneumoniae* outbreaks in 2006 and 2013 (45). There are difficulties in distinguishing this presentation from *Mycoplasma pneumoniae* or pneumonia caused by respiratory viruses. Despite earlier notions suggesting that hoarseness and laryngitis were more prevalent in *Chlamydia pneumoniae* infection than in *Mycoplasma pneumoniae* infection, previous comparisons of clinical characteristics have indicated the opposite (46,47).

It has been reported that rhinitis, cough and hoarseness were notably more prevalent in *Mycoplasma pneumoniae* infection compared with *Chlamydia pneumoniae* infection (47). The same researchers observed that C-reactive protein (CRP) and aspartate aminotransferase levels were substantially higher in *Chlamydia pneumoniae* infection than in *Mycoplasma pneumoniae* infection. However, other clinical symptoms and laboratory findings between the two pathogens did not exhibit significant differences (47) according to an earlier study, patients with pneumonia caused by both *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* have notably lower CRP and white blood cell values than in those with pneumonia caused by *Streptococcus pneumoniae* (46).

No specific symptom, laboratory marker, or combination of findings reliably distinguishes *C. pneumoniae*-induced pneumonia from that caused by other respiratory pathogens. Additionally, concurrent infection with other pathogens alongside *Chlamydia pneumoniae* can affect the clinical presentation (45).

Pneumonia stemming from *Mycoplasma pneumoniae* often presents a challenging clinical scenario due to its mild and ambiguous symptoms, such as myalgias, cervical adenopathy, nonproductive cough and fatigue, rendering differentiation from other viral upper respiratory infections and atypical bacterial infections difficult (32,48,49).

Mycoplasma pneumoniae commonly affects children attending school and young adults, often causing outbreaks during the autumn season (32,48-50). These outbreaks typically affect individuals in close contact with infected patients within households or confined spaces (51). Apart from its

unconventional symptoms, the manifestations of *Mycoplasma pneumoniae* can differ markedly, spanning from mild upper respiratory symptoms to pneumonia and various manifestations unrelated to the lungs. These include cardiovascular, dermatological and central nervous system symptoms, even without the presence of pneumonia (52).

Legionella infections manifest primarily in two forms: i) Legionnaires' disease, a severe pneumonia resulting from *Legionella* infection. It often involves multiple body systems, notably the lungs and gastrointestinal tract, with associated significant mortality rates (53). ii) Pontiac fever is a mild, self-limiting flu-like illness. Pontiac fever is characterized by mild fever, chills, myalgia, and headaches lasting 2-5 days, typically resolving without substantial mortality (54).

While *Legionella* primarily affects individuals aged ≥ 50 years, instances have been documented in infants and neonates (55). Distinguishing Legionnaires' disease from pneumonia caused by other pathogens can be challenging due to similar clinical symptoms; however, the presence of diarrhea and heightened creatinine kinase levels may signal a *Legionella* infection (10). *Legionella*-induced pneumonia often occurs in clusters, but not through person-to-person transmission, typically stemming from exposure to the same infection source. Contaminated water or soil largely account for *Legionella* infections. Risk factors include rainfall, high humidity, and working in gardens with compost (56-58). Although the majority of cases of Legionnaires' disease are associated with *Legionella pneumophila*, several other bacterial species have been identified as causative agents of *Legionella* lung infections (58,59).

Zoonotic atypical CAPs stemming from Q fever, psittacosis or tularaemia typically manifest following exposure to their respective carriers. Notably, psittacosis stands as an outlier, potentially transmissible through contact with healthy or ailing psittacine birds. By contrast, incidences of tularaemia and Q fever CAP are not arbitrary; establishing a recent epidemiological background is imperative before suspecting these diagnoses. Should a patient displaying atypical pneumonia lack a recent contact history associated with psittacosis, Q fever, or tularaemia, the likelihood of a zoonotic atypical CAP is exceedingly low (19-22). Thus, it can reasonably be inferred that the patient is experiencing a non-zoonotic atypical pneumonia linked to *Legionella*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae* (59).

Collectively, pneumonia caused by *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella* species presents with distinct clinical features. *Chlamydia pneumoniae* typically leads to a milder, more insidious onset of symptoms, including a prolonged cough, low-grade fever, and common respiratory symptoms, such as a sore throat and hoarseness. *Mycoplasma pneumoniae* often affects younger populations, with a gradual onset characterized by a dry cough, fever and extrapulmonary manifestations, such as skin rashes and neurological symptoms. By contrast, *Legionella* infections, particularly *Legionella pneumophila*, cause a more severe form of pneumonia known as Legionnaires' disease. This presents with high fever, chills, myalgia and prominent gastrointestinal symptoms, such as diarrhea, often accompanied by neurological signs, such as confusion. *Legionella pneumophila* progresses rapidly and can lead to severe,




Figure 2. Imaging techniques and characteristics and comparison of laboratory investigations. Parts of this image derived from the free medical site <http://smart.servier.com/> (accessed on 15 December 2023) by Servier, licenced under a Creative Commons Attribution 3.0 Unported Licence.

potentially life-threatening outcomes, particularly in older adults and individuals with underlying health conditions (60).

Imaging. An illustration of the imaging techniques and characteristics, and comparison of laboratory investigations for the detection of infection is presented in Fig. 2. As regards *Chlamydia pneumoniae*, initially, chest radiographs typically reveal a unilateral pattern of alveolar infiltrates or consolidation, often limited to a single lobe. The lower lobe involvement is more frequent than detecting lesions in the middle or upper lobe (60-63). Instances of interstitial pneumonia manifest relatively infrequently. Approximately a quarter of patients may exhibit small to moderate pleural effusions, while findings, such as hilar or mediastinal lymphadenopathy are less commonly observed in chest radiographs. Variations in findings may hinge on the timing of imaging during the illness, the diagnostic method used, and the exclusion of concomitant respiratory pathogens. In a previous study involving 55 patients classified with primary infection, initial chest radiographs depicted predominantly unilateral findings, while subsequent radiographs taken around 3.8 days later revealed predominantly bilateral findings (61).

In a previous retrospective analysis of thin-section CT scans from 24 patients with serologically diagnosed with CAP caused by *Chlamydia pneumoniae*, Nambu *et al* (64) observed a marked increase in airway dilation compared to *Streptococcus pneumoniae* or *Mycoplasma pneumoniae*-related pneumonia cases, along with a higher incidence of pulmonary emphysema compared to *Mycoplasma pneumoniae* cases, but not *Streptococcus pneumoniae* cases. Their study suggested that the elevated airway dilation and pulmonary emphysema may stem from pre-existing obstructive lung disease rather than the infection itself (64). Despite significant findings in pulmonary emphysema and airway dilation, neither these nor other CT scan observations were able to reliably distinguish *Chlamydia pneumoniae*-related pneumonia from that caused by other pathogens (64). Overall, CT scan or radiograph results in *C. pneumoniae* cases exhibit broad variability and lack specificity for identifying the pathogen as the cause of pneumonia (61-64).

The imaging characteristics of *Mycoplasma pneumoniae* infections mirror their elusive nature. Chest radiographs commonly reveal diffuse interstitial patterns, occasionally disproportionate to the physical symptoms of patients. On chest CT scans, the interstitial alterations apparent in the radiographs manifest as tree-in-bud formations (65). In a 2016 prospective study by Gong *et al* (65) involving 1,280 pediatric cases of pneumonia caused by *Mycoplasma pneumoniae* between 2010 and 2014, a substantial proportion of patients exhibited extensive patchy infiltrates, both unilateral and bilateral, suggesting that the diagnosis of pneumonia could not be solely determined based on imaging characteristics.

Legionellosis chest radiographs have been described in multiple reports (66,67). While some attempts have been made to outline specific patterns indicative of *Legionella*, the radiographic findings in *Legionella* infection demonstrate significant variability, predominantly influenced by the timing of the radiograph in the course of the illness. Certain temporal features, however, can augment the probability of diagnosing *Legionella* pneumonitis. Initially, poorly defined focal infiltrates are common, with around 10% concurrent with pleural effusion. These infiltrates tend to progress to adjacent lobes, eventually becoming bilateral, with pleural effusions occurring in about 35% of cases. This progression often persists despite appropriate antimicrobial treatment and even in the presence of clinical improvement. Immunocompromised individuals exhibit a similar pattern, often displaying a high incidence of cavitation and hilar adenopathy. A lengthy resolution phase, lasting up to 6 months, frequently occurs, occasionally resulting in residual densities. Attempts to associate radiographic characteristics with disease severity and mortality have had limited success (68).

Collectively, imaging studies reveal distinct patterns for each type of pneumonia. *Chlamydia pneumoniae* typically presents on a chest X-ray with diffuse interstitial infiltrates, often patchy or involving the lower lobes, with occasional segmental consolidation. *Mycoplasma pneumoniae* is usually associated with reticulonodular patterns or patchy consolidations on an X-ray, predominantly in the lower lobes, and occasionally, hilar lymphadenopathy. CT scans may reveal

bronchial wall thickening and centrilobular nodules. By contrast, pneumonia caused by *Legionella* is characterized by rapidly progressing lobar consolidation, often with bilateral involvement on chest X-ray. CT imaging may reveal dense consolidations, nodular opacities, ground-glass changes and sometimes small pleural effusions, reflecting the more aggressive and widespread nature of this infection (69).

Laboratory investigations. Established methods to detect *Chlamydia pneumoniae* infection involve serological studies and the culture or PCR analysis of respiratory tract samples. An organized discussion of the different testing methods is provided below:

Serological tests. Traditionally, the diagnosis of *Chlamydia pneumoniae* infection has hinged on serology, necessitating a 4-fold increase in IgG or IgA levels between acute and convalescent serum samples. Serological approaches are generally intricate as patients must return after 4 to 6 weeks from the initial presentation to confirm the diagnosis retrospectively. Moreover, this retrospective nature renders serological outcomes minimally impactful on treatment decisions. Different serological criteria used for diagnosis upon initial presentation, such as a serum IgM antibody titer of 1:16 or higher, strongly depend on when the sample was collected. This is due to the potential absence of a titer rise early in acute infection or reinfection. Depending entirely on initial serologic samples for diagnosis, without confirming retrospectively using convalescent serum samples, poses the risk of overlooking 25 to 33% of infections. The initial serological testing could require several days to produce results, further limiting their utility in making initial management decisions. Possible cross-reactivity between *Chlamydia pneumoniae* antigens and antigens from other *Chlamydia* species limits the specificity of serological techniques. Microimmunofluorescence is considered the gold standard for serological diagnosis (70,71).

ELISA, an alternative method, may be less intricate and more objectively interpretable than microimmunofluorescence (69). However, complement fixation is not recommended for diagnosis due to its limited sensitivity and specificity (70,72).

PCR technology. Considering the constraints of serology and culture, the PCR analysis of respiratory samples has become the preferred diagnostic method. Multiplex PCR can assess multiple potential respiratory pathogens without a significant decrease in sensitivity compared to singleplex PCR testing (73). In 2012, the FDA sanctioned the FilmArray Respiratory Panel, employing multiplex PCR to identify *Chlamydia pneumoniae* and other microorganisms from nasopharyngeal swabs (74). PCR, however, faces specificity limitations due to asymptomatic carriage and persistent identification of *Chlamydia pneumoniae* on respiratory swabs even after clinical symptom resolution, possibly extending for several weeks to months following antibiotic therapy (75,76). This persistence complicates definitively attributing positive PCR results to persistent infection, reinfection, or ongoing asymptomatic carriage, potentially involving other pathogens (76). Moreover, *Chlamydia pneumoniae* detection in respiratory samples does not exclude coinfection with other pathogens, affecting clinical presentation as observed in

multiple studies (72,76). Other detection methods include identifying *Chlamydia* lipopolysaccharide in circulation or the presence of *Chlamydia pneumoniae* in circulating phagocytes or atheromas. However, these approaches are technically complex and presently restricted to research settings (70).

Traditionally, the diagnosis of *Mycoplasma pneumoniae* relied on cultures and serology, with culture isolation once deemed the gold standard. However, due to the slow and inconsistent growth of *Mycoplasma pneumoniae*, routine culturing is no longer common and offers limited clinical utility (48,50). Other diagnostic avenues include serologic studies using ELISA to quantify bacterial antibody expression, microparticle agglutination and complement fixation assays. Definitive diagnosis in serologic studies required paired sera demonstrating a significant 4-fold increase in IgG or subsequent seroconversion 3-4 weeks later (77-80). Yet, due to delayed antibody production and seroconversion, these tests hold limited utility for the diagnosis of acute *Mycoplasma pneumoniae* infections in clinical settings and are more retrospective for epidemiological studies (50,77-79).

As culture and serology have shortcomings in the diagnosis of *Mycoplasma pneumoniae*, diagnostic methods are shifting toward faster molecular techniques, such as nucleic acid amplification. Molecular diagnostics enable the timely detection of *Mycoplasma pneumoniae* infections and are increasingly pivotal in clinical diagnosis. An array of laboratory techniques, such as nucleic acid amplification, multilocus variable number tandem-repeat analysis, and multilocus sequence typing, are becoming prominent (50). These tests deliver rapid, highly specific, and sensitive results (50,77). Several tests employ real-time PCR to target specific gene regions of *Mycoplasma pneumoniae*, including those encoding the P1 gene, 16S ribosomal RNA, the ATPase operon, and the community-acquired respiratory distress syndrome toxin (50,77-80). This technology has led to multiplex PCR development, allowing for the detection of various atypical pathogens, including *Chlamydia pneumoniae*, *Chlamydia psittaci*, *Legionella* species and other respiratory viruses (50,72). Nonetheless, debate persists over which sample types provide the best sensitivity and specificity for these assays. Studies have suggested that sputum samples yield more positive results compared to nasopharyngeal aspirates, nasopharyngeal swabs, or oropharyngeal swabs (79,81).

Since numerous aspects of *Legionella* closely resemble both typical and atypical pneumonias, relying on clinical symptoms or radiological evidence offers limited diagnostic value. The CDC indeed relies on several methods to confirm *Legionella* infections. These include culturing *Legionella* bacteria from respiratory samples, such as sputum or bronchoalveolar lavage, detecting the *Legionella* antigen in urine, or observing a significant increase (≥ 4 -fold) in *Legionella*-specific antibodies in the blood serum of patients when comparing acute and convalescent samples (82). PCR-based diagnostic tests, although demonstrating specificity and sensitivity in ongoing assessments, are pending approval by the FDA. Other methods, such as direct immunostaining, are being utilized to identify the bacterium, but often necessitate invasive procedures to procure tissue for testing (83).

Culture methods. Culture, although considered specific due to a low asymptomatic carriage rate, has limited sensitivity

due to the slow and fastidious growth of *Chlamydia* species, often requiring weeks (68,84,85). Previous studies indicate a minimal frequency of growth in culture, even when infection is identified through serology or PCR (68). Some researchers in 2010 (84) discouraged routine culture use due to the inability to detect any positive results among 6,981 respiratory specimens, despite *Chlamydia* species accounting for 5 to 22% of CAP and other respiratory infections.

Due to the challenging nature of isolating *Chlamydia psittaci*, its diagnosis relies entirely on serological methods. In individuals lacking immunity or prior exposure, heightened tube agglutination tests for *Chlamydia psittaci* serve as a definitive diagnostic tool. Similarly, the diagnosis of tularemia and Q fever relies on serology due to the highly infectious, perilous and elusive nature of these organisms. In individuals lacking immunity or previous exposure, acute increases in *Francisella tularensis* IgM/IgG levels serve as diagnostic indicators. As regards Q fever or tularemia, apart from initially elevated acute titers, the diagnosis of these zoonotic CAPs is contingent upon a 4-fold increase in titers between acute and convalescent samples taken 4-8 weeks apart (83).

Collectively, the diagnosis of atypical pneumonia can be achieved through several methods, each with distinct advantages and limitations. Serologic testing, while widely available and cost-effective, often suffers from delayed diagnosis due to the need for paired sera to detect rising antibody titers, and it may produce false positives due to cross-reactivity with other pathogens (6,71). Culture methods offer high specificity and allow for direct pathogen identification and susceptibility testing; however, they are time-consuming, have a low sensitivity and require specialized media, rendering them less practical for routine diagnostics (72,83). PCR assays provide a highly sensitive and specific method for early pathogen detection, delivering rapid results that can significantly impact patient management. However, PCR is more costly, requires specialized equipment and may detect non-viable organisms, complicating the interpretation of positive results (60,75). Combining these methods can enhance diagnostic accuracy, particularly in complex cases of atypical pneumonia.

4. Treatment

The antibiotic treatment recommendations (Fig. 3) for *Chlamydia pneumoniae* face limitations due to the absence of standardized diagnostic criteria and reliance on serology alone in most past studies. The 2007 guidelines from the Infectious Diseases Society of America (IDSA) acknowledge a lack of robust evidence supporting specific antibiotic therapies for this pathogen (85). Consequently, treatment suggestions are still largely based on expert opinions. In cases where symptoms reappear after a standard antibiotic course, experts recommend prolonged treatment upon identification of *Chlamydia* species (70).

Effective antibiotic therapy against *Chlamydia pneumoniae* necessitates intracellular penetration due to its nature as an obligate intracellular microorganism. Antibiotic classes, such as macrolides, tetracyclines and fluoroquinolones, which disrupt DNA and protein synthesis, display *in vitro* activity against this pathogen, thus becoming the recommended drugs for clinical treatment (86).




Figure 3. Schematic illustration providing a summary of recommended antibiotics, special considerations for each pathogen and novel treatments under investigation.

Macrolide and tetracycline antibiotics are effective against atypical pathogens, such as *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella* species, primarily due to their ability to penetrate and act within host cells, targeting intracellular processes. These atypical pathogens are often intracellular or lack the typical cell wall structure, which renders them inherently resistant to β -lactam antibiotics such as penicillin (4).

Among fluoroquinolones, ciprofloxacin exhibits a higher minimum inhibitory concentration compared to others in this class, potentially reducing its efficacy. Notably, *Chlamydia pneumoniae* exhibits resistance to trimethoprim, sulfonamides, aminoglycosides and glycopeptides. While penicillin and amoxicillin display *in vitro* activity against *Chlamydia* species, they are not recommended as routine therapies for *Chlamydia pneumoniae*. Resistance to the recommended treatments is infrequent and does not appear to contribute to treatment ineffectiveness or the persistence of *Chlamydia pneumoniae* identified in respiratory samples following the

completion of therapy. This is evidenced by isolates obtained from patients following appropriate therapy, displaying *in vitro* sensitivity (86).

Three new antimicrobial agents, solithromycin, nemonoxacin and AZD0914, have exhibited *in vitro* activity against *Chlamydia* species but are currently undergoing trial phases and await FDA approval for treatment (87-89). Nemonoxacin, a new fluoroquinolone, demonstrates *in vitro* effectiveness similar to that of azithromycin, doxycycline and levofloxacin (88). Clinical trials involving 256 and 192 patients with mild to moderately severe CAP have demonstrated the effectiveness of nemonoxacin in treating all identified patients with *Chlamydia pneumoniae*, albeit a total of only 9 patients between both trials (90-91).

Solithromycin, a novel fourth-generation macrolide, has been shown to exhibit *in vitro* activity against *Chlamydia* species and has demonstrated non-inferiority to moxifloxacin in a phase III clinical trial for CAP treatment; however, that study did not specifically identify patients with *Chlamydia* infection (92). AZD0914 exhibits potent activity against *Chlamydia* species and various other respiratory pathogens *in vitro* as a bacterial DNA gyrase/topoisomerase inhibitor. Nevertheless, it is not currently undergoing clinical investigation for respiratory infection treatment (88).

Infection caused by *Mycoplasma pneumoniae* often goes undetected, as patients tend to forgo seeking treatment due to the gradual onset of symptoms (32,48,49). The bacterium has an extended incubation period of ~3 weeks, and symptomatic shedding can persist for up to 4 months; however, the majority of cases naturally resolve within 2 to 4 weeks without treatment (32,48,77).

When patients seek clinical care, their treatment is commonly directed by the IDSA guidelines for CAP, considering the symptoms of the patient and imaging outcomes (93). *Mycoplasma pneumoniae*, being a small bacterium lacking a cell wall, inherently resists β -lactam antimicrobials. Despite this, it is usually treated in empirical CAP treatment with macrolide, often in the absence of a confirmed laboratory diagnosis. This antimicrobial treatment has the potential to reduce the duration of the illness, requiring a course of antibiotics ranging from 5 days to 2 weeks, depending on the selected antibiotic for individuals affected by the infection (94,95). Due to its prevalence among children and young adults, macrolides have become the preferred treatment choice. Tetracyclines and fluoroquinolones, while effective, are associated with unfavorable side-effects that are more problematic in younger patients, such as dentition discoloration with tetracyclines and tendinitis with fluoroquinolones (95).

Managing extrapulmonary symptoms or complex cases of *Mycoplasma pneumoniae* infection beyond antibiotic treatment remains uncertain in terms of specific treatment protocols. For patients with *Mycoplasma pneumoniae*-associated extrapulmonary conditions, understanding the inflammatory nature of the bacteria is crucial (96). Through pathways linked to Toll-like receptor 2, the bacteria can prompt pro-inflammatory cytokine production and inflammasome activity. This could clarify why symptoms are more common among young adults, as they typically have a stronger immune response compared to infants or elderly patients who may not generate the same level of response (97). In patients with central nervous system

complications or severe pneumonia caused by *Mycoplasma pneumoniae*, there have been reports suggesting the potential benefits of steroids and immunoglobulin therapy, although these findings have not been validated in clinical trials (56,98). Additionally, for severe pneumonia leading to acute respiratory distress syndrome, reports indicate potential benefits from extracorporeal membrane oxygenation and the use of steroids (56,79,81).

The primary treatment for pneumonia due to *Legionella* involves antibiotics. Failure to administer appropriate antimicrobial treatment at an early stage is linked to high mortality rates (99,100). Selecting the right antibiotic is not solely based on its *in vitro* ability to kill or inhibit bacteria, but also on its capacity to penetrate host tissue cell membranes, where *Legionella* resides. Among the most commonly used and highly effective antibiotics for treating Legionnaires' disease are fluoroquinolones and macrolides. Including these agents in the initial treatment plan is advisable when *Legionella* infection is suspected due to local outbreaks, travel history or extrapulmonary symptoms (86).

Early reports from the initial outbreak of Legionnaires' disease found that tetracycline and erythromycin were more effective than other antibiotics, such as β -lactams, while the use of steroids was linked to unfavorable outcomes (53). Erythromycin, a historically preferred antibiotic, has exhibited high effectiveness against Legionnaires' disease, but may cause notable side-effects, particularly when administered intravenously (100-103). Azithromycin, another macrolide, has demonstrated high efficacy with fewer side-effects in treating Legionella infection, often used when erythromycin does not yield results (104,105).

Clarithromycin, rifampin, ciprofloxacin and doxycycline are other effective antibiotics against *Legionella*, either used individually or in combination with erythromycin (98). Research findings suggest that fluoroquinolones demonstrate effectiveness comparable to, or even greater than, erythromycin in treating Legionnaires' disease. Levofloxacin has exhibited a high efficacy, with shorter periods of hospitalization and early clinical responses, becoming a favored antibiotic for this condition (40,106-108).

While the majority of antibiotic therapies span 5 to 10 days and effectively treat *Legionella* infection, immunocompromised patients may require longer durations, up to 3 weeks. Administration routes vary based on infection severity, with parenteral therapy preferred for severe cases, transitioning to oral treatment once a positive response is observed (101).

Antibiotic resistance in *Legionella* species is rarely reported in clinical settings, although *in vitro* resistance has been observed. Previous reports have highlighted instances of fluoroquinolone resistance in patients undergoing treatment, emphasizing the need for close monitoring during ongoing antibiotic therapy (109,110). Table I summarizes the effective therapies for atypical pneumonia microorganisms.

Increased antibiotic resistance in the treatment of atypical pneumonia, caused by pathogens such as *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and *Legionella* species, can significantly affect treatment outcomes and disease progression. When atypical pneumonia pathogens, particularly *Mycoplasma pneumoniae*, develop resistance to commonly

Table I. Most effective therapies for atypical pneumonia.

Microorganism	Effective therapies
<i>Chlamydia pneumoniae</i>	Macrolides, tetracyclines, fluoroquinolones
<i>Mycoplasma pneumoniae</i>	Macrolides, tetracyclines, fluoroquinolones
<i>Legionella</i> species	Fluoroquinolones, macrolides
<i>Chlamydia psittaci</i> (psittacosis)	Tetracyclines (e.g., doxycycline), macrolides (e.g., azithromycin), fluoroquinolones
<i>Coxiella burnetii</i> (Q fever)	Tetracyclines (e.g., doxycycline), fluoroquinolones
<i>Francisella tularensis</i> (tularemia)	Aminoglycosides (e.g., streptomycin, gentamicin), tetracyclines (e.g., doxycycline), fluoroquinolones

used antibiotics, such as macrolides (e.g., azithromycin, clarithromycin), patients may experience delayed a clinical improvement. For instance, macrolide-resistant *Mycoplasma pneumoniae* has been increasingly reported, particularly in Asia. In cases where macrolide resistance is present, the initial antibiotic therapy may fail, leading to prolonged symptoms, such as persistent cough, fever and malaise, and necessitating the use of alternative antibiotics such as fluoroquinolones or tetracyclines, which may have a broader side-effect profile. Antibiotic resistance can lead to more severe disease progression due to ineffective initial treatment. For example, in *Legionella* infections, delayed or inappropriate antibiotic therapy due to resistance can result in a higher risk of complications, such as acute respiratory distress syndrome (ARDS), multi-organ failure, or even death, particularly in vulnerable populations, such as the elderly or immunocompromised patients. The timely administration of effective antibiotics is critical in treating Legionnaires' disease, and resistance can undermine this, leading to more aggressive disease progression.

Resistance to first-line antibiotics often requires switching to second- or third-line treatments, which may be less effective, more toxic, or more expensive. For instance, patients with macrolide-resistant *Chlamydia pneumoniae* may require alternative treatments, such as doxycycline or fluoroquinolones, which could extend the duration of therapy and hospitalization. This not only increases healthcare costs, but also places patients at higher risk of hospital-acquired infections and other complications associated with prolonged hospital stays. In some cases, antibiotic resistance can lead to the failure to completely eradicate the infection, resulting in chronic or recurrent pneumonia. This is particularly concerning in *Chlamydia pneumoniae* infections, where resistance can lead to a chronic, low-grade infection that persists despite treatment, potentially contributing to the chronic inflammatory state and associated complications, such as chronic bronchitis or worsening of chronic obstructive pulmonary disease (COPD).

When antibiotic-resistant atypical pneumonia is not adequately treated, there is a higher risk of ongoing transmission, particularly in community or healthcare settings. For example, patients with macrolide-resistant *Mycoplasma pneumoniae* may remain infectious for a longer period of time, leading to outbreaks in settings, such as schools, military barracks, or long-term care facilities, where close contact facilitates the spread of infection (111-113).

5. Prognosis

Pneumonia caused by atypical pathogens typically presents as mild or moderate, although its progression to severe pneumonia often results in a fatal outcome (6). A previous retrospective study revealed that among patients with pneumonia infected with *Chlamydia pneumoniae*, ARDS developed in 6 out of 11 cases (114). The mortality rate was notably high, reaching 83% among those with APACHE II scores ≥ 12 and 100% among those with CURB-65 scores ≥ 2 (114). Detecting multi-lobe involvement at an earlier stage is crucial. In Europe, a previous study involving patients with pneumonia averaging 66 years of age highlighted a worse prognosis among elderly patients with *Legionella pneumophila* infection (115). That study reported an overall mortality rate as high as 23%, with a majority of fatalities attributed to UK community-acquired *Legionella pneumophila* infections (115). Complications arising from atypical pathogen infections extend beyond the respiratory system, leading to a poorer prognosis. These complications include damage to various organs such as the heart, liver, kidneys, blood system and mucous membranes. Atypical pathogen infections can exacerbate conditions, such as COPD, induce bronchial asthma, progress to ARDS and potentially increase the risk of lung cancer. In cases of the acute exacerbation of COPD, atypical pathogens, predominantly *Mycoplasma pneumoniae* and *Chlamydia pneumoniae*, account for 5-10% of cases, with as many as 14% associated with *Mycoplasma pneumoniae* and 5.0-8.9% with *Chlamydia pneumoniae* infections (116). Interaction between *Chlamydia pneumoniae* infection and allergic inflammation may exacerbate the symptoms of asthma (117,118). *Legionella pneumophila* pneumonia tends to progress to ARDS more frequently compared to other pathogens (41). While the association between *Chlamydia pneumoniae* infection and lung cancer remains debatable, studies suggest a potential link (119-122). Complications in the cardiovascular system induced by atypical pathogen infections include coronary artery disease, myocardial infarction, unstable angina, atherosclerosis and cerebral infarction. Studies have shown a higher incidence of *Chlamydia pneumoniae* infections among patients with coronary artery disease (CAD), with implications for myocardial infarction and the occurrence of more extensive vessel lesions. Antibiotic treatment, particularly with azithromycin, has exhibited positive correlations with the secondary prevention of CAD. Additionally, *Chlamydia pneumoniae* infection

has been significantly associated with an increased risk of cerebral infarction (123-125). Extrapulmonary complications, such as hepatic function insufficiency and septic shock, also arise. Severe-atypical CAP has been shown to present significantly in Vietnamese children, with various factors such as age, co-infection with bacteria and viruses, and respiratory/cardiac system malformations significantly associated with its severity (126). Increasing antibiotic resistance poses a critical factor affecting prognosis. The widespread use of antibiotics has prompted atypical pathogens to alter their form, structure and metabolism, complicating antibiotic treatment. Reports from Japan, Germany, France and China have highlighted increasing macrolide resistance rates in *Mycoplasma pneumoniae* strains, necessitating longer antibiotic therapy durations and delayed fever resolution in macrolide-resistant cases. Alternative therapies with moxifloxacin or levofloxacin have been employed for macrolide-resistant strains (95,127-129). Patients infected with macrolide-resistant *Mycoplasma pneumoniae* have experienced more persistent symptoms, leading to therapeutic changes from macrolides to tetracycline or fluoroquinolone for a more rapid clinical improvement. Macrolide-resistant groups have exhibited a higher incidence of extrapulmonary complications, such as liver function abnormalities, myocarditis, rash and encephalitis, along with more severe radiological findings compared to macrolide-sensitive groups. The interplay between drug resistance and complications contributes to severe clinical symptoms, prolonged illnesses and a worse prognosis (130,131). The treatment of pneumonia caused by *Chlamydia psittaci* typically involves antibiotics. Tetracyclines, such as doxycycline or tetracycline itself, are often considered the first-line treatment for psittacosis. Macrolides, such as azithromycin, and fluoroquinolones can also be effective alternatives for treating this type of pneumonia. The duration of antibiotic treatment and specific medication choice may vary based on the severity of the infection, the overall health of the patient and any existing medical conditions (132,133).

In the case that a patient does not respond to treatment for atypical pneumonia, it is important to consider alternative diagnoses, including lung adenocarcinoma, particularly in the case that symptoms persist or worsen. The key difference is that while atypical pneumonia is an infectious disease that typically responds to antibiotics or antiviral treatments, lung adenocarcinoma is a type of cancer that may present with similar respiratory symptoms, such as cough and chest discomfort, but will not improve with antimicrobial therapy. Instead, lung adenocarcinoma often requires further analyses through imaging studies, such as a CT scan, and possibly a biopsy to confirm the diagnosis and guide appropriate oncological treatment. Therefore, in the case that there is no clinical improvement with standard pneumonia treatments, lung adenocarcinoma should be considered as a potential underlying cause, prompting further diagnostic evaluation (134).

6. Conclusions and future perspectives

In conclusion, atypical pneumonia, caused by diverse pathogens, such as *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella* species, presents diagnostic

challenges due to its varied symptoms and systemic impact. Despite this complexity, antibiotics targeting intracellular processes have proven effective, though antibiotic resistance poses a growing concern. While *Streptococcus pneumoniae* remains a primary cause, atypical pathogens significantly contribute to cases, particularly among young adults and in outpatient settings. Diagnosis methods, while valuable, have limitations in accuracy. The prognosis of atypical pneumonia varies widely, potentially leading to severe complications beyond the respiratory system and impacting overall health. Managing this condition demands a nuanced approach considering the diverse pathogens involved and their varied clinical impacts.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

DAS and VEG conceptualized the study. IGL, KT, PS, NT, VEG and DAS made a substantial contribution to the interpretation and analysis of the data from the literature to be included in the review, and wrote and prepared the draft of the manuscript. DAS and VEG analyzed the data from the literature to be included in the review and provided critical revisions. All authors contributed to manuscript revision, and all authors have read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

Use of artificial intelligence tools

During the preparation of this work, AI tool Chat GPT was used to improve the readability and language of the manuscript, and subsequently, the authors revised and edited the content produced by the AI tool as necessary, taking full responsibility for the ultimate content of the present manuscript.

References

1. Murray HW and Tuazon C: Atypical pneumonias. *Med Clin North Am* 64: 507-527, 1980.
2. Martin RE and Bates JH: Atypical pneumonia. *Infect Dis Clin North Am* 5: 585-601, 1991.
3. Blasi F: Atypical pathogens and respiratory tract infections. *Eur Respir J* 24: 171-181, 2004.
4. Garin N, Marti C, Skali Lami A and Prendki V: Atypical pathogens in adult community-acquired pneumonia and implications for empiric antibiotic treatment: A narrative review. *Microorganisms* 10: 2326, 2022.
5. Gong C, Zhang T, Luo M, Li A, Dong M, Li M, Wang Y and Huang F: Distribution of the atypical pathogens of community-acquired pneumonia to disease severity. *J Thorac Dis* 10: 5991-6001, 2018.
6. Cunha BA: The atypical pneumonias: Clinical diagnosis and importance. *Clin Microbiol Infect* 12 (Suppl 3): S12-S24, 2006.
7. Cheng YJ, Lin KY, Chen CC, Huang YL, Liu CE and Li SY: Zoonotic atypical pneumonia due to *Chlamydophila psittaci*: First reported psittacosis case in Taiwan. *J Formos Med Assoc* 112: 430-433, 2013.
8. Lynch JP III, Clark NM: Pneumonia | Atypical. *Encyclopedia of Respiratory Medicine* 2006: 410-417, 2006.
9. Woodhead MA and Macfarlane JT: Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. *Br J Dis Chest* 81: 133-139, 1987.
10. Sopena N, Sabrià-Leal M, Pedro-Botet ML, Padilla E, Dominguez J, Morera J and Tudela P: Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. *Chest* 113: 1195-1200, 1998.
11. Mulazimoglu L and Yu VL: Can Legionnaires disease be diagnosed by clinical criteria? A critical review. *Chest* 120: 1049-1053, 2001.
12. Fernández-Sabé N, Rosón B, Carratalà J, Dorca J, Manresa F and Gudiol F: Clinical diagnosis of Legionella pneumonia revisited: Evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. *Clin Infect Dis* 37: 483-489, 2003.
13. Gupta SK and Sarosi GA: The role of atypical pathogens in community-acquired pneumonia. *Med Clin North Am* 85: 1349-1365, vii, 2001.
14. Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J, Menzella F, Blasi F, *et al*: Atypical pathogens in hospitalized patients with community-acquired pneumonia: A worldwide perspective. *BMC Infect Dis* 18: 677, 2018.
15. Cunha BA: Antibiotic pharmacokinetic considerations in pulmonary infections. *Semin Respir Infect* 6: 168-182, 1991.
16. Schüler P, Zemper K, Borner K, Koeppe P, Schaberg T and Lode H: Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. *Eur Respir J* 10: 1130-1136, 1997.
17. Honeybourne D: Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. *Curr Opin Pulm Med* 3: 170-174, 1997.
18. Muller-Serieys C, Soler P, Cantalloube C, Lemaitre F, Gia HP, Brunner F and Andremont A: Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). *Antimicrob Agents Chemother* 45: 3104-3108, 2001.
19. Esposito S and Principi N: Asthma in children: Are chlamydia or mycoplasma involved? *Paediatr Drugs* 3: 159-168, 2001.
20. Daian CM, Wolff AH and Bielory L: The role of atypical organisms in asthma. *Allergy Asthma Proc* 21: 107-111, 2000.
21. MacDowell AL and Bacharier LB: Infectious triggers of asthma. *Immunol Allergy Clin North Am* 25: 45-66, 2005.
22. Micillo E, Bianco A, D'Auria D, Mazzarella G and Abbate GF: Respiratory infections and asthma. *Allergy* 55 (Suppl 61): S42-S45, 2000.
23. Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagianti A and Penco M: Chlamydia pneumoniae infection and atherosclerotic coronary disease. *Am Heart J* 137: 1116-1119, 1999.
24. Ericson K, Saldeen TG, Lindquist O, Pålsson C and Mehta JL: Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. *Circulation* 101: 2568-2571, 2000.
25. Zamorano J, García-Tejada J, Suárez A, Culebras E, Castañón J, Moreno R, Reguillo F, Gil M, Picazo J and Sánchez-Harguindey L: Chlamydia pneumoniae in the atherosclerotic plaques of patients with unstable angina undergoing coronary artery bypass grafting: Does it have prognostic implications? *Int J Cardiol* 90: 297-302, 2003.
26. Weinberg AN: Respiratory infections transmitted from animals. *Infect Dis Clin North Am* 5: 649-661, 1991.
27. Gill V and Cunha BA: Tularemia pneumonia. *Semin Respir Infect* 12: 61-67, 1997.
28. Stubbs R, Dralle W and Williams J: Psittacosis pneumonia. *J Tenn Med Assoc* 82: 189-190, 1989.
29. Cotton EM, Strampfer MJ and Cunha BA: Legionella and mycoplasma pneumoniae—a community hospital experience with atypical pneumonias. *Clin Chest Med* 8: 441-453, 1987.
30. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM Jr, Rello J, *et al*: A worldwide perspective of atypical pathogens in community-acquired pneumonia. *Am J Respir Crit Care Med* 175: 1086-1093, 2007.
31. Wang S, Tang J, Tan Y, Song Z and Qin L: Prevalence of atypical pathogens in patients with severe pneumonia: A systematic review and meta-analysis. *BMJ Open* 13: e066721, 2023.
32. Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, Mensa J and Torres A: Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax* 66: 340-346, 2011.
33. Capelastegui A, España PP, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, Lopez de Goicoechea MJ, Gorordo I, Esteban C, *et al*: Etiology of community-acquired pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. *BMC Infect Dis* 12: 134, 2012.
34. Spoorenberg SM, Bos WJ, Heijligenberg R, Voorn PG, Grutters JC, Rijkers GT and van de Garde EM: Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia: an observational analysis. *BMC Infect Dis* 14: 335, 2014.
35. Van Gageldonk-Lafeber AB, Wever PC, van der Lubben IM, de Jager CP, Meijer A, de Vries MC, Elberse K, van der Sande MA and van der Hoek W: The aetiology of community-acquired pneumonia and implications for patient management. *Neth J Med* 71: 418-425, 2013.
36. Shibli F, Chazan B, Nitzan O, Flatau E, Edelstein H, Blondheim O, Raz R and Colodner R: Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. *Isr Med Assoc J* 12: 477-482, 2010.
37. Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B, Cao B, Sun T, Hu Y, Xiu Q, *et al*: Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. *BMC Infect Dis* 9: 31, 2009.
38. Tao LL, Hu BJ, He LX, Wei L, Xie HM, Wang BQ, Li HY, Chen XH, Zhou CM and Deng WW: Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China. *Chin Med J (Engl)* 125: 2967-2972, 2012.
39. Chen K, Jia R, Li L, Yang C and Shi Y: The aetiology of community associated pneumonia in children in Nanjing, China and aetiological patterns associated with age and season. *BMC Public Health* 15: 113, 2015.
40. Arancibia F, Cortes CP, Valdés M, Cerda J, Hernández A, Soto L and Torres A: Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile. *Chest* 145: 290-296, 2014.
41. Luchsinger V, Ruiz M, Zunino E, Martínez MA, Machado C, Piedra PA, Fasce R, Ulloa MT, Fink MC, Lara P, *et al*: Community-acquired pneumonia in Chile: The clinical relevance in the detection of viruses and atypical bacteria. *Thorax* 68: 1000-1006, 2013.
42. Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, Sarosi GA, Grayston JT, Summersgill J and YU VL: Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective, randomized, multicenter trial. *Arch Intern Med* 160: 1294-1300, 2000.
43. Sopena N, Sabrià M, Pedro-Botet ML, Manterola JM, Matas L, Domínguez J, Modol JM, Tudela P, Ausina V and Foz M: Prospective study of community-acquired pneumonia of bacterial etiology in adults. *Eur J Clin Microbiol Infect Dis* 18: 852-858, 1999.

44. Viasus D, Di Yacovo S, Garcia-Vidal C, Verdagner R, Manresa F, Dorca J, Gudiol F and Carratalà J: Community-acquired *Legionella pneumophila* pneumonia: A single-center experience with 214 hospitalized sporadic cases over 15 years. *Medicine (Baltimore)* 92: 51-60, 2013.
45. Conklin L, Adjemian J, Loo J, Mandal S, Davis C, Parks S, Parsons T, McDonough B, Partida J, Thurman K, *et al*: Investigation of a *Chlamydia pneumoniae* outbreak in a Federal correctional facility in Texas. *Clin Infect Dis* 57: 639-647, 2013.
46. Miyashita N, Fukano H, Okimoto N, Hara H, Yoshida K, Niki Y and Matsushima T: Clinical presentation of community-acquired *Chlamydia pneumoniae* pneumonia in adults. *Chest* 121: 1776-1781, 2002.
47. Puljiz I, Kuzman I, Dakovic-Rode O, Schönwald N and Mise B: *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* pneumonia: Comparison of clinical, epidemiological characteristics and laboratory profiles. *Epidemiol Infect* 134: 548-555, 2006.
48. Yu Y and Fei A: Atypical pathogen infection in community-acquired pneumonia. *Biosci Trends* 10: 7-13, 2016.
49. Reinton N, Manley L, Tjate T and Moghaddam A: Respiratory tract infections during the 2011 *Mycoplasma pneumoniae* epidemic. *Eur J Clin Microbiol Infect Dis* 32: 835-840, 2013.
50. Diaz MH and Winchell JM: The evolution of advanced molecular diagnostics for the detection and characterization of *Mycoplasma pneumoniae*. *Front Microbiol* 7: 232, 2016.
51. Brown RJ, Nguipod-Djomo P, Zhao H, Stanford E, Spiller OB and Chalker VJ: *Mycoplasma pneumoniae* Epidemiology in England and Wales: A National Perspective. *Front Microbiol* 7: 157, 2016.
52. Narita M: Classification of extrapulmonary manifestations due to *Mycoplasma pneumoniae* infection on the basis of possible pathogenesis. *Front Microbiol* 7: 23, 2016.
53. Fraser DW, Tsai TR, Orenstein W, Parkin WE, Beecham HJ, Sharrar RG, Harris J, Mallison GF, Martin SM, McDade JE, *et al*: Legionnaires' disease: Description of an epidemic of pneumonia. *N Engl J Med* 297: 1189-1197, 1977.
54. Glick TH, Gregg MB, Berman B, Mallison G, Rhodes WW Jr and Kassanoff I: Pontiac fever. An epidemic of unknown etiology in a health department: I. Clinical and epidemiologic aspects. *Am J Epidemiol* 107: 149-160, 1978.
55. Levy I and Rubin LG: Legionella pneumonia in neonates: A literature review. *J Perinatol* 18: 287-290, 1998.
56. Garcia AV, Fingeret AL, Thirumoorathi AS, Kadenhe-Chiweshe A and Kandel JJ: Severe *Mycoplasma pneumoniae* infection requiring extracorporeal membrane oxygenation with concomitant ischemic stroke in a child. *Pediatr Pulmonol* 48: 98-101, 2013.
57. Fisman DN, Lim S, Wellenius GA, Johnson C, Britz P, Gaskins M, Maher J, Mittleman MA, Spain CV, Haas CN and Newbern C: It's not the heat, it's the humidity: Wet weather increases legionellosis risk in the greater Philadelphia metropolitan area. *J Infect Dis* 192: 2066-2073, 2005.
58. Graham FF, White PS, Harte DJ and Kingham SP: Changing epidemiological trends of legionellosis in New Zealand, 1979-2009. *Epidemiol Infect* 140: 1481-1496, 2012.
59. Johnson DH and Cunha BA: Atypical pneumonias. Clinical and extrapulmonary features of *Chlamydia*, *Mycoplasma*, and *Legionella* infections. *Postgrad Med* 93: 69-72, 75-76, 79-82, 1993.
60. Sharma L, Losier A, Tolbert T, Dela Cruz CS and Marion CR: Atypical Pneumonia: Updates on legionella, chlamydia, and mycoplasma pneumonia. *Clin Chest Med* 38: 45-58, 2017.
61. McConnell CT Jr, Plouffe JF, File TM, Mueller CF, Wong KH, Skelton SK, Marston BJ and Breiman RF: Radiographic appearance of *Chlamydia pneumoniae* (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study. *Radiology* 192: 819-824, 1994.
62. Kauppinen MT, Lähde S and Syrjälä H: Roentgenographic findings of pneumonia caused by *Chlamydia pneumoniae*. A comparison with streptococcus pneumonia. *Arch Intern Med* 156: 1851-1856, 1996.
63. Boersma WG, Daniels JM, Löwenberg A, Boeve WJ and van de Jagt EJ: Reliability of radiographic findings and the relation to etiologic agents in community-acquired pneumonia. *Respir Med* 100: 926-932, 2006.
64. Nambu A, Saito A, Araki T, Ozawa K, Hiejima Y, Akao M, Ohki Z and Yamaguchi H: *Chlamydia pneumoniae*: Comparison with findings of *Mycoplasma pneumoniae* and *Streptococcus pneumoniae* at thin-section CT. *Radiology* 238: 330-338, 2006.
65. Gong L, Zhang CL and Zhen Q: Analysis of clinical value of CT in the diagnosis of pediatric pneumonia and mycoplasma pneumonia. *Exp Ther Med* 11: 1271-1274, 2016.
66. Mittal S, Singh A, Gold M, Leung AN, Haramati LB and Katz DS: Thoracic imaging features of Legionnaire's disease. *Infect Dis Clin North Am* 31: 43-54, 2017.
67. Evans AF, Oakley RH and Whitehouse GH: Analysis of the chest radiograph in Legionnaires' disease. *Clin Radiol* 32: 361-365, 1981.
68. Tan MJ, Tan JS, Hamor RH, File TM Jr and Breiman RF: The radiologic manifestations of Legionnaire's disease. The ohio community-based pneumonia incidence study group. *Chest* 117: 398-403, 2000.
69. Garg M, Prabhakar N, Gulati A, Agarwal R and Dhooria S: Spectrum of imaging findings in pulmonary infections. Part 1: Bacterial and viral. *Pol J Radiol* 84: e205-e213, 2019.
70. Burillo A and Bouza E: *Chlamydia pneumoniae*. *Infect Dis Clin North Am* 24: 61-71, 2010.
71. Puolakkainen M: Laboratory diagnosis of persistent human chlamydial infection. *Front Cell Infect Microbiol* 3: 99, 2013.
72. Verkooyen RP, Willemsse D, Hiep-van Casteren SC, Joulandan SA, Snijder RJ, van den Bosch JM, van Helden HP, Peeters MF and Verbrugh HA: Evaluation of PCR, culture, and serology for diagnosis of *Chlamydia pneumoniae* respiratory infections. *J Clin Microbiol* 36: 2301-2307, 1998.
73. Thurman KA, Warner AK, Cowart KC, Benitez AJ and Winchell JM: Detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella* spp. in clinical specimens using a single-tube multiplex real-time PCR assay. *Diagn Microbiol Infect Dis* 70: 1-9, 2011.
74. Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, Smith P and Schachter J: Persistent infection with *Chlamydia pneumoniae* following acute respiratory illness. *Clin Infect Dis* 14: 178-182, 1992.
75. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, *et al*: Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *N Engl J Med* 373: 415-427, 2015.
76. Loens K and Ieven M: *Mycoplasma pneumoniae*: Current knowledge on nucleic acid amplification techniques and serological diagnostics. *Front Microbiol* 7: 448, 2016.
77. Youn YS and Lee KY: *Mycoplasma pneumoniae* pneumonia in children. *Korean J Pediatr* 55: 42-47, 2012.
78. Loens K, Ursi D, Goossens H and Ieven M: Molecular diagnosis of *Mycoplasma pneumoniae* respiratory tract infections. *J Clin Microbiol* 41: 4915-4923, 2003.
79. Herrera M, Aguilar YA, Rueda ZV, Muskus C and Vélez LA: Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria. *J Negat Results Biomed* 15: 3, 2016.
80. Loens K, Van Heirstraeten L, Malhotra-Kumar S, Goossens H and Ieven M: Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections. *J Clin Microbiol* 47: 21-31, 2009.
81. Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, Lortholary O, Zumla A and Abubakar I: Epidemiology and clinical management of Legionnaires' disease. *Lancet Infect Dis* 14: 1011-1021, 2014.
82. Avni T, Bieber A, Green H, Steinmetz T, Leibovici L and Paul M: Diagnostic Accuracy of PCR Alone and compared to urinary antigen testing for detection of legionella spp: A systematic review. *J Clin Microbiol* 54: 401-411, 2016.
83. Nieuwenhuizen AA, Dijkstra F, Notermans DW and van der Hoek W: Laboratory methods for case finding in human psittacosis outbreaks: A systematic review. *BMC Infect Dis* 18: 442, 2018.
84. She RC, Thurber A, Hymas WC, Stevenson J, Langer J, Litwin CM and Petti CA: Limited utility of culture for *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* for diagnosis of respiratory tract infections. *J Clin Microbiol* 48: 3380-3382, 2010.
85. Hyman CL, Roblin PM, Gaydos CA, Quinn TC, Schachter J and Hammerschlag MR: Prevalence of asymptomatic nasopharyngeal carriage of *Chlamydia pneumoniae* in subjectively healthy adults: Assessment by polymerase chain reaction-enzyme immunoassay and culture. *Clin Infect Dis* 20: 1174-1178, 1995.
86. Kohlhoff SA and Hammerschlag MR: Treatment of Chlamydial infections: 2014 update. *Expert Opin Pharmacother* 16: 205-212, 2015.

87. Roblin PM, Kohlhoff SA, Parker C and Hammerschlag MR: In vitro activity of CEM-101, a new fluoroketolide antibiotic, against *Chlamydia trachomatis* and *Chlamydia (Chlamydophila) pneumoniae*. *Antimicrob Agents Chemother* 54: 1358-1359, 2010.
88. Chotikanatis K, Kohlhoff SA and Hammerschlag MR: In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against *Chlamydia trachomatis* and *Chlamydia pneumoniae*. *Antimicrob Agents Chemother* 58: 1800-1801, 2014.
89. Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, and Bradford PA: In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant gram-positive and fastidious gram-negative pathogens. *Antimicrob Agents Chemother* 59: 6053-6063, 2015.
90. Van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, Ho ML, Chang LW, Chung DT, Chang YT, *et al*: Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. *Antimicrob Agents Chemother* 54: 4098-4106, 2010.
91. Liu Y, Zhang Y, Wu J, Zhu D, Sun S, Zhao L, Wang X, Liu H, Ren Z, Wang C, *et al*: A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. *J Microbiol Immunol Infect* 50: 811-820, 2017.
92. Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, *et al*: Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: A global, double-blind, multi-centre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). *Lancet Infect Dis* 16: 421-430, 2016.
93. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, *et al*: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 44 (Suppl 2): S27-S72, 2007.
94. Kashyap S and Sarkar M: Mycoplasma pneumonia: Clinical features and management. *Lung India* 27: 75-85, 2010.
95. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, Zhang JZ, Liu YM, Zhang YY, Wang H and Wang C: High prevalence of macrolide resistance in *Mycoplasma pneumoniae* isolates from adult and adolescent patients with respiratory tract infection in China. *Clin Infect Dis* 51: 189-194, 2010.
96. Shimizu T: Inflammation-inducing Factors of *Mycoplasma pneumoniae*. *Front Microbiol* 7: 414, 2016.
97. Principi N and Esposito S: Emerging role of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in paediatric respiratory-tract infections. *Lancet Infect Dis* 1: 334-344, 2001.
98. Sánchez-Vargas FM and Gómez-Duarte OG: *Mycoplasma pneumoniae*-an emerging extra-pulmonary pathogen. *Clin Microbiol Infect* 14: 105-117, 2008.
99. Gacouin A, Le Tulzo Y, Lavoue S, Camus C, Hoff J, Bassen R, Arvieux C, Heurtin C and Thomas R: Severe pneumonia due to *Legionella pneumophila*: prognostic factors, impact of delayed appropriate antimicrobial therapy. *Intensive Care Med* 28: 686-691, 2002.
100. Heath CH, Grove DI and Looke DF: Delay in appropriate therapy of *Legionella pneumoniae* associated with increased mortality. *Eur J Clin Microbiol Infect Dis* 15: 286-290, 1996.
101. Edelstein PH: Legionnaires' disease. *Clin Infect Dis* 16: 741-747, 1993.
102. Swanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY and Yu VL: Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. *Am J Med* 92: 61-68, 1992.
103. Howden BP, Stuart RL, Tallis G, Bailey M and Johnson PD: Treatment and outcome of 104 hospitalized patients with legionnaires' disease. *Intern Med J* 33: 484-488, 2003.
104. Plouffe JF, Breiman RF, Fields BS, Herbert M, Inverso J, Knirsch C, Kolokathis A, Marrie TJ, Nicolle L and Schwartz DB: Azithromycin in the treatment of *Legionella pneumoniae* requiring hospitalization. *Clin Infect Dis* 37: 1475-1480, 2003.
105. Dorrell L, Fulton B and Ong EL: Intravenous azithromycin as salvage therapy in a patient with Legionnaire's disease. *Thorax* 49: 620-621, 1994.
106. Sabrià M, Pedro-Botet ML, Gómez J, Roig J, Vilaseca B, Sopena N and Baños V; Legionnaires Disease Therapy Group: Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. *Chest* 128: 1401-1405, 2005.
107. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX and Tenenber AM: Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. *Curr Med Res Opin* 20: 555-563, 2004.
108. Burdet C, Lepeule R, Duval X, Caseris M, Rioux C, Lucet JC and Yazdanpanah Y: Quinolones versus macrolides in the treatment of legionellosis: A systematic review and meta-analysis. *J Antimicrob Chemother* 69: 2354-2360, 2014.
109. Bruin JP, Koshkolda T, IJzerman EP, Lück C, Diederer BM, Den Boer JW and Mouton JW: Isolation of ciprofloxacin-resistant *Legionella pneumophila* in a patient with severe pneumonia. *J Antimicrob Chemother* 69: 2869-2871, 2014.
110. Shadoud L, Almahmoud I, Jarraud S, Etienne J, Larrat S, Schwebel C, Timsit JF, Schneider D and Maurin M: Hidden Selection of Bacterial Resistance to Fluoroquinolones In Vivo: The Case of *Legionella pneumophila* and Humans. *EBioMedicine* 2: 1179-1185, 2015.
111. Arnold FW, Summersgill JT and Ramirez JA: Role of atypical pathogens in the etiology of community-acquired pneumonia. *Semin Respir Crit Care Med* 37: 819-828, 2016.
112. Georgakopoulou VE, Lempesis IG, Sklapani P, Trakas N and Spandidos DA: Exploring the pathogenetic mechanisms of *Mycoplasma pneumoniae* (Review). *Exp Ther Med* 28: 271, 2024.
113. Waites KB, Xiao L, Liu Y, Balish MF and Atkinson TP: *Mycoplasma pneumoniae* from the respiratory tract and beyond. *Clin Microbiol Rev* 30: 747-809, 2017.
114. Liu KT, Yang KY, Lee YC and Perng RP: Risk factor analysis of acute respiratory distress syndrome among hospitalized patients with *Chlamydia pneumoniae* pneumonia. *J Chin Med Assoc* 70: 318-323, 2007.
115. Wingfield T, Rowell S, Peel A, Puli D, Guleri A and Sharma R: Legionella pneumonia cases over a five-year period: A descriptive, retrospective study of outcomes in a UK district hospital. *Clin Med (Lond)* 13: 152-159, 2013.
116. Housset B: Rising to the challenge of resistance: A case study-based discussion. *Int J Antimicrob Agents* 29 (Suppl 1): S11-S16, 2007.
117. Cunningham AF, Johnston SL, Julious SA, Lampe FC and Ward ME: Chronic *Chlamydia pneumoniae* infection and asthma exacerbations in children. *Eur Respir J* 11: 345-349, 1998.
118. Von Hertzen L, Töyrylä M, Gimishanov A, Bloigu A, Leinonen M, Saikku P and Haahtela T: Asthma, atopy and *Chlamydia pneumoniae* antibodies in adults. *Clin Exp Allergy* 29: 522-528, 1999.
119. Koyi H, Brandén E, Gnärpe J, Gnärpe H and Steen B: An association between chronic infection with *Chlamydia pneumoniae* and lung cancer. A prospective 2-year study. *APMIS* 109: 572-580, 2001.
120. Kocazeybek B: Chronic *Chlamydia pneumoniae* infection in lung cancer, a risk factor: A case-control study. *J Med Microbiol* 52: 721-726, 2003.
121. Littman AJ, White E, Jackson LA, Thornquist MD, Gaydos CA, Goodman GE and Vaughan TL: *Chlamydia pneumoniae* infection and risk of lung cancer. *Cancer Epidemiol Biomarkers Prev* 13: 1624-1630, 2004.
122. Koh WP, Chow VT, Phoon MC, Ramachandran N and Seow A: Lack of association between chronic *Chlamydia pneumoniae* infection and lung cancer among nonsmoking Chinese women in Singapore. *Int J Cancer* 114: 502-504, 2005.
123. Xue L, Liang YH, Gao YY and Wang XJ: Clinical study of *chlamydia pneumoniae* infection in patients with coronary heart disease. *BMC Cardiovasc Disord* 19: 110, 2019.
124. Dogra J: Oral azithromycin in extended dosage schedule for chronic, subclinical *Chlamydia pneumoniae* infection causing coronary artery disease: A probable cure in sight? Results of a controlled preliminary trial. *Int J Gen Med* 5: 505-509, 2012.
125. Su X and Chen HL: *Chlamydia pneumoniae* infection and cerebral infarction risk: A meta-analysis. *Int J Stroke* 9: 356-364, 2014.
126. Huong Ple T, Hien PT, Lan NT, Binh TQ, Tuan DM and Anh DD: First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1-15 years. *BMC Public Health* 14: 1304, 2014.

127. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K and Ubukata K; Acute Respiratory Diseases Study Group: Increased macrolide resistance of *Mycoplasma pneumoniae* in pediatric patients with community-acquired pneumonia. *Antimicrob Agents Chemother* 52: 348-350, 2008.
128. Dumke R, von Baum H, Lück PC and Jacobs E: Occurrence of macrolide-resistant *Mycoplasma pneumoniae* strains in Germany. *Clin Microbiol Infect* 16: 613-616, 2010.
129. Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM and Pereyre S: Increased macrolide resistance of *Mycoplasma pneumoniae* in France directly detected in clinical specimens by real-time PCR and melting curve analysis. *J Antimicrob Chemother* 64: 52-58, 2009.
130. Principi N and Esposito S: Macrolide-resistant *Mycoplasma pneumoniae*: Its role in respiratory infection. *J Antimicrob Chemother* 68: 506-511, 2013.
131. Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z and Chen Z: More complications occur in macrolide-resistant than in macrolide-sensitive *Mycoplasma pneumoniae* pneumonia. *Antimicrob Agents Chemother* 58: 1034-1038, 2014.
132. Gautam J and Krawiec C: *Chlamydia Pneumonia*. StatPearls Publishing, Treasure Island, FL, 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560874/>.
133. Marchese S, Marchese G, Paviglianiti G, Lapi M, Ottoveggio G, Pipitone G and Corsello G: A pediatric case of *Chlamydia psittaci* caused severe Acute Respiratory Distress Syndrome (ARDS) in Italy. *Ital J Pediatr* 49: 107, 2023.
134. Hashimoto K, Nishimura S and Akagi M: Lung adenocarcinoma presenting as a soft tissue metastasis to the shoulder: A case report. *Medicina (Kaunas)* 57: 181, 2021.



Copyright © 2024 Georgakopoulou et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.